At the heart of miRNA-mediated immunoregulation lies a dynamic interplay with central immune signalling cascades, notably the NF-κB, MAPK, JAK-STAT, and TGF-β/Smad pathways. Viral proteins, alongside host-produced cytokines, trigger these pathways through pattern recognition receptors (PRRs) that form the frontline detection system against invading pathogens. These cascades transduce signals essential for immune cell activation and cytokine secretion, but miRNAs fine-tune these responses by differentially targeting nodes within these pathways, ensuring an immune balance that can either favor viral clearance or promote chronic infection.

The NF-κB pathway, activated by viral components like the SARS-CoV-2 spike protein, HIV Tat and Nef, HBV X protein, and HSV glycoprotein B, is subject to nuanced regulation by miRNAs. This pathway’s activation amplifies inflammatory signals upon recognition of pathogens via PRRs such as Toll-like receptor 4 (TLR4). Studies highlight miR-155 and miR-30e-5p as positive regulators enhancing NF-κB signalling, while miR-21, miR-146a, and its isoform miR-146a-5p serve as negative feedback modulators curbing excessive inflammation. Interestingly, HSV-specific host miRNAs exhibit context-dependent influences, demonstrating the complexity of miRNA function during infection.

Parallel to NF-κB control, the IL-1 receptor-mediated MAPK cascade undergoes regulation by diverse miRNAs targeting upstream kinases and adaptor proteins. miR-146a suppresses IRAK1 and TRAF6, thereby attenuating the IL-1R-MyD88-dependent MAP3K activation, which otherwise leads to the phosphorylation of p38 MAPK and the subsequent activation of the AP-1 transcription factor complex (Fos/Jun). Contrastingly, miR-16-2-3p and miR-618 bolster p38 phosphorylation, enhancing AP-1-driven pro-inflammatory gene expression, with miR-939 further promoting IL-8 transcription. Thus, miRNA networks modulate the fine balance between pro- and anti-inflammatory signals pivotal in viral pathogenesis.

The receptor tyrosine kinase (RTK)-MAPK pathway, which processes signals from growth factors and viral proteins such as HIV gp120 and HBV X protein, is tightly modulated by miRNAs influencing intracellular signal relay. miR-93 targets the adaptor protein GRB2, diminishing RTK-induced MAPK activation, whereas miR-1246 amplifies ERK signalling leading to increased cytokine production. Moreover, miR-212-3p directly represses MAPK1/ERK, attenuating HBV envelope antigen (HBeAg)-induced inflammatory cytokine secretion. These divergent miRNA effects highlight virus-specific exploitation of this pathway to modify host immune responses.

Central to regulating immune suppression, fibrosis, and cell cycle control is the TGF-β/SMAD pathway, modulated by both viral and host miRNAs. HSV-encoded miRNAs such as miR-H2, miR-H3, and miR-H4 target SMAD3/4 proteins, effectively disrupting the nuclear complex essential for downstream gene regulation. Host-derived miR-145 also negatively regulates SMAD3, reflecting a convergence of viral and host miRNAs in immune modulation. Additionally, miR-369-3p influences T-cell receptor (TCR), Notch, and IL-4 signalling during HSV infection, thus altering T-cell polarization and immune outcome.

The JAK-STAT pathway is a principal mediator of interferon and cytokine signalling, critical for antiviral defense. Its responsiveness is fine-tuned by a spectrum of miRNAs: inhibitory miR-150-5p tempers signalling amplitude, while activating miRNAs such as HBV-miR-3, miR-7, and miR-18a enhance pathway activity. Notably, SARS-CoV-2 encodes miRNAs capable of robustly suppressing the JAK-STAT axis, facilitating immune evasion and viral survival. This opposing regulation exemplifies the adaptive complexity of viral miRNA strategies versus host defenses.

Despite these distinct viruses differing in tropism and life cycles, a subset of miRNAs—miR-21, miR-146a, miR-150, and miR-155—consistently emerges as a conserved core in regulating immune responses. These miRNAs orchestrate cytokine production, immune cell differentiation, and antiviral mechanisms by targeting shared transcriptional regulators. Yet, the downstream cellular effects vary: HIV predominantly involves T-cell regulation, HBV modulates antigen processing and natural killer (NK) cell cytotoxicity, HSV impacts NK-cell activity and T-cell polarization, while SARS-CoV-2 primarily alters type I interferon responses. Such differential targeting underscores a shared molecular strategy employed by diverse viruses through distinct immunological routes.

The interface of viral-encoded and host-derived miRNAs reveals a sophisticated regulatory layer often underappreciated. Viral miRNAs can compete with host miRNAs for binding sites, act as competitive endogenous RNA (ceRNA) sponges, or co-target immune-related genes, subtly tuning infection progression. In HSV-1, latent-associated transcript (LAT)-encoded miRNAs like miR-H2 antagonize host miR-155, dampening inflammation and favoring viral latency. Similarly, HBV’s HBV-miR-3 modulates both viral replication and host pathways, sustaining chronic infection states. These interactions highlight viral evolution in exploiting miRNA biology to balance immune evasion and coexistence.

Crucially, miRNA-mediated regulation exhibits marked cell-type specificity and temporal dynamics. A single miRNA may impose divergent effects depending on the immune cell subset and infection phase. For example, miR-146a-5p attenuates NF-κB activation in macrophages, reducing inflammation, whereas miR-146a-3p promotes pro-inflammatory functions in other immune cells. Likewise, miR-150-5p typically undergoes early downregulation to enhance antiviral responses, followed by normalization facilitating inflammation resolution. These spatiotemporal differences reflect intricate control at transcriptional, cytokine feedback, and epigenetic levels, challenging therapeutic exploitation but offering nuanced intervention points.

The clinical potential of miRNAs extends beyond mechanistic insight; circulating miRNAs represent stable, accessible biomarkers reflecting immune activation status, viral load, and therapeutic responses. Such miRNAs hold promise in diagnostic and prognostic applications, facilitating personalized medicine approaches during viral infections. On the therapeutic front, strategies to inhibit pro-inflammatory miRNAs via antagomirs or enhance anti-inflammatory ones with mimics and extracellular vesicle (EV)-based delivery systems are gaining traction to restore immune homeostasis and limit pathology.

Further, viral miRNAs themselves constitute attractive therapeutic targets or vaccine adjuncts. Their roles in latency, immune modulation, and viral persistence underscore their significance. Targeting viral miRNAs could disrupt infection maintenance while boosting host immunity. Conversely, using viral miRNAs as adjuvants may refine vaccine efficacy by modulating host immune responses in beneficial ways.

Despite these advances, several challenges persist. The context-dependent nature of miRNA regulation demands precise characterization across immune cell types and infection stages. Additionally, interplay with other non-coding RNAs and cellular factors warrants deeper investigation. Comprehensive experimental approaches integrating transcriptomics, proteomics, and functional assays will be crucial to untangle these layers and guide translational applications.

Ultimately, the convergence of diverse viruses on a limited set of immune signalling nodes via miRNA-mediated mechanisms provides a unifying conceptual framework. This paradigm not only enhances our understanding of viral pathogenesis but also illuminates pathways ripe for targeted interventions. Efforts accelerating miRNA research promise to unlock novel diagnostics and therapeutics, transforming the clinical management of viral infections with global health implications.

Subject of Research: miRNA-mediated immunoregulation in viral infections, focusing on SARS-CoV-2, HBV, HIV, and HSV.

Article Title: Decoding miRNA-Mediated Immunoregulation in SARS-CoV-2, HBV, HIV, and HSV Infections.

Article References:
Arziman, S., Aydemir, S., & Bozok, V. Decoding miRNA-Mediated Immunoregulation in SARS-CoV-2, HBV, HIV, and HSV Infections. Genes Immun (2026). https://doi.org/10.1038/s41435-026-00376-4

Image Credits: AI Generated

DOI: 10.1038/s41435-026-00376-4

Keywords: microRNA, immunoregulation, SARS-CoV-2, HBV, HIV, HSV, NF-κB, MAPK, JAK-STAT, TGF-β/Smad, viral miRNAs, immune evasion, antiviral responses.

Autophagy, a fundamental cellular process that maintains homeostasis by degrading and recycling cellular components, has long been recognized for its role in infection and immunity. RB1CC1/FIP200 serves as a core regulator within the autophagy pathway, coordinating the formation of autophagosomes — the vesicles responsible for sequestering cytoplasmic materials destined for degradation. The study elucidates how mutations disrupting the function of RB1CC1 perturb autophagic flux, consequently compromising antiviral defenses during SARS-CoV-2 infection.

Leveraging comprehensive genomic screening techniques, the investigators performed next-generation sequencing on cohorts of COVID-19 patients exhibiting severe disease phenotypes. They discovered a significant enrichment of rare, loss-of-function variants in RB1CC1 among these individuals compared to controls with milder or asymptomatic infections. These variants effectively decrease RB1CC1 protein expression or alter its conformation, thereby inhibiting its ability to nucleate autophagosome biogenesis, which is paramount to cellular quality control and antiviral responses.

Mechanistic assays involving cell lines and primary immune cells from affected subjects confirmed that RB1CC1 deficiency impairs the autophagy machinery’s capacity to clear viral components. This deficiency leads to heightened cellular stress and aberrant immune signaling, disrupting the delicate balance of host-pathogen interactions. Notably, cells harboring RB1CC1 mutations showed diminished interferon responses, a critical arm of the antiviral immune response that typically restricts viral replication and spread.

The impaired autophagy resulting from RB1CC1 variants also seems to affect antigen presentation pathways in professional antigen-presenting cells, such as dendritic cells and macrophages. Autophagy facilitates processing and presentation of viral antigens on major histocompatibility complex molecules, enabling the activation of adaptive immunity. By hindering this process, defective RB1CC1 impairs the host’s capacity to mount a robust T cell-mediated response to SARS-CoV-2, further exacerbating susceptibility to severe disease.

Importantly, this research extends beyond a mere genetic association by providing compelling experimental evidence that restoring RB1CC1 function can reverse immune deficits. Using gene-editing technology and pharmacological enhancers of autophagy, the team was able to rescue autophagic flux and reinforce antiviral defenses in vitro. These findings position RB1CC1 as a promising therapeutic target for ameliorating COVID-19 severity and potentially other viral infections where autophagy plays a protective role.

The implications of this study are vast, especially considering the ongoing evolution of SARS-CoV-2 variants and the persistent burden of breakthrough infections. The identification of autophagy impairment as a determinant of COVID-19 severity underscores the necessity of personalized medicine approaches. Genetic screening for RB1CC1 variants could allow early stratification of patients at higher risk, enabling tailored interventions such as autophagy modulators or immune-boosting therapies.

Moreover, this insight may help explain the observed heterogeneity in vaccine responses. Individuals with compromised autophagy due to RB1CC1 mutations might exhibit suboptimal immunogenicity or durability of vaccine-induced protection. Understanding such genetic factors can lead to improved vaccine designs or adjunct therapies that enhance efficacy by correcting autophagic defects.

The study also highlights the broader role of autophagy in antiviral immunity, reinforcing the concept that cellular catabolic pathways serve dual functions in cellular maintenance and host defense. It invites further exploration into how viruses like SARS-CoV-2 exploit or evade autophagic processes to establish infection and persist, providing avenues for novel antiviral strategies.

In addition to virus-related immunity, RB1CC1 has been implicated in various physiological processes including cell growth, differentiation, and neurodegeneration. Thus, the deleterious variants identified may have pleiotropic effects, contributing to the complex clinical manifestations witnessed in COVID-19, such as long COVID symptoms and neurological sequelae, through dysfunctional autophagy.

This work, published in Nature Communications, represents a multidisciplinary collaboration involving genomic medicine, cell biology, immunology, and clinical research. It underscores the power of integrative approaches to unravel the host determinants of infectious disease outcomes, providing a template for future investigations into genetic susceptibilities that modulate immune defenses.

As the scientific community continues to grapple with the challenges posed by emergent pathogens, the elucidation of RB1CC1’s role in antiviral immunity not only enriches our molecular understanding but also paves the way for innovative therapeutic interventions. These findings may ultimately inform public health strategies, contributing to reducing COVID-19 mortality and morbidity worldwide.

Moving forward, clinical trials assessing autophagy-enhancing drugs in genetically predisposed individuals could validate the translational potential of these discoveries. Furthermore, expanding genetic surveillance to include additional autophagy-related genes might uncover a broader spectrum of vulnerabilities, facilitating comprehensive risk profiling for infectious diseases.

This pioneering research is a testament to the dynamic interplay of genetics and immune regulation in determining disease trajectories, marking a significant advance in infectious disease biology. It offers hope that through molecular precision, we can identify those at greatest risk and intervene effectively, transforming the management of viral pandemics.

In sum, the identification of deleterious variants in RB1CC1/FIP200 as critical modulators of immunity to SARS-CoV-2 provides a vital nexus between autophagy dysregulation and heightened disease susceptibility. The study invites a reexamination of autophagic pathways as central players in antiviral immunity and heralds a new frontier in understanding and combating infectious diseases through genetic insights.

Subject of Research: Genetic determinants of immune response to SARS-CoV-2, focusing on the autophagy-related gene RB1CC1/FIP200 and its impact on antiviral immunity.

Article Title: Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2.

Article References:
Hu, L., van der Sluis, R.M., Castelino, K.B. et al. Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Nat Commun 16, 10618 (2025). https://doi.org/10.1038/s41467-025-65308-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65308-8

While the initial surge of neutralizing antibodies following mRNA vaccination has been well-documented, the intricate dynamics of antibody waning and the comparative longevity of hybrid immunity have remained elusive until now. Roe and colleagues employed advanced statistical models to estimate the decay rates of antibodies, capturing how immunity evolves weeks and months post-vaccination or infection. This nuanced perspective challenges earlier notions of uniform antibody decline, illuminating heterogeneity in immune durability among individuals and immune contexts.

Central to this study is the modeling of protective immunity as a decay curve rather than a simplistic binary status. The researchers amassed data from multiple cohorts receiving mRNA vaccines, including Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273, along with individuals possessing hybrid immunity resulting from natural infection followed by vaccination. By fitting decay models to longitudinal antibody measurements, the team quantified the half-life of these protective antibodies, offering precise estimates grounded in real-world immunological observations.

Remarkably, their findings underscore that hybrid immunity confers a more prolonged antibody presence compared to vaccination alone. Protective antibodies in individuals with prior infection combined with mRNA vaccination displayed significantly slower decay rates, suggesting a more robust and durable immune shield. This phenomenon likely stems from the immune system’s enhanced memory B cell repertoire and breadth of response induced by exposure to multiple viral antigens through infection and vaccine.

The implications for public health policies are substantial. If hybrid immunity truly offers extended protection, this could influence booster dose deployment strategies, prioritizing vaccine-only recipients with more rapid antibody decline. Furthermore, appreciating the variable kinetics of antibody waning enables tailoring vaccine schedules to optimize population immunity over time, especially in the face of emerging viral variants.

Roe et al.’s study also navigates the complexities of assay variability and antibody threshold definitions when estimating protective immunity. Recognizing that antibody levels correlate with protection but are not absolute predictors, the work integrates statistical uncertainty and heterogeneity among individuals, marking a methodological advancement in the field. This statistical rigor enhances the reliability and applicability of the findings in guiding real-world immunity assessments.

Moreover, the study may inform the design of next-generation vaccines. Understanding the immunological underpinnings of hybrid immunity’s superior durability could drive innovations that mimic natural infection’s antigenic exposure without risk, possibly through multivalent or heterologous vaccine formulations. Such strategies would better prepare humanity for future coronavirus threats and the dynamic evolutionary nature of SARS-CoV-2.

The temporal decay of antibodies is only one facet of immune memory, however; T cell responses and mucosal immunity also contribute to long-lasting defense. While this investigation centers on humoral immunity, its insights emphasize the necessity for comprehensive immunological surveillance to fully grasp vaccine efficacy over time. Future studies integrating multi-pronged immune analyses will be vital to paint a complete picture of COVID-19 immunity landscape.

Countries grappling with vaccine distribution disparities and emerging variants stand to benefit from this research’s guidance on prioritizing limited resources. By quantifying the durability of protection, health authorities can make informed decisions on booster timing and provide clear communication to the public regarding their evolving immune status post-vaccination or infection.

The study also reiterates the critical importance of longitudinal sampling in immune surveillance. Cross-sectional snapshots may overlook individual trajectories and the breadth of immune responses; this research’s modeling approach leverages repeated measurements to precisely capture antibody kinetics, underscoring the value of sustained data collection efforts.

As we march deeper into the vaccination era and the pandemic’s endemic phase, insights into antibody durability will increasingly govern strategies for achieving sustainable herd immunity and mitigating breakthrough infections. Roe et al.’s meticulous quantification of decay rates provides an empirically supported foundation upon which such tactics can be constructed.

This work also invites a re-examination of the concept of sterilizing immunity versus protection from severe disease. Declining antibody titers may no longer prevent infection, but may still reduce disease severity and transmission. The integration of antibody decay modeling with clinical outcome data will further refine our comprehension of immunity’s protective spectrum.

In conclusion, this seminal research represents a crucial leap in our quantitative understanding of SARS-CoV-2 immunity dynamics. By estimating the intricate temporal decay of protective antibodies elicited by mRNA vaccines and hybrid immunity, Roe and colleagues enable a more rational and evidence-based path forward in managing COVID-19 through vaccination efforts.

By revealing the relative durability advantage of hybrid immunity and illuminating the kinetics of antibody waning, this study equips scientists, clinicians, and policymakers with essential knowledge to calibrate public health interventions in the ongoing quest to tame the COVID-19 crisis.

Subject of Research: Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity.

Article Title: Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity.

Article References:
Roe, M.D., Coggins, S.A., Darcey, E.S. et al. Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity. npj Viruses 3, 76 (2025). https://doi.org/10.1038/s44298-025-00156-3

Image Credits: AI Generated

Neutrophils are typically known for their essential role in the innate immune response, serving as the first line of defense against invading pathogens. They have a remarkable ability to destroy bacteria and other harmful microorganisms, essentially acting as the body’s defense warriors. However, the dynamics change when the body encounters SARS-CoV-2. According to the study’s senior author, Dr. Andrea Cox, neutrophils appear to undergo a significant reprogramming process that compromises their ability to combat the virus effectively. Instead of executing their regular immune functions, these cells transform into polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), which paradoxically inhibit the actions of other immune cells crucial for viral defense.

The transition of neutrophils into PMN-MDSCs raises critical questions about the broader implications for immune health during COVID-19 infections. Historically, PMN-MDSCs have been linked to various conditions such as cancer, where they play a role in suppressing T lymphocytes—our body’s primary immune fighters. This study suggests that a similar mechanism might be at play in severe COVID-19 cases, wherein PMN-MDSCs actively hinder T cell function and effectiveness during viral threats.

Notably, previous research hinted at elevated neutrophil counts in patients who develop severe manifestations of COVID-19, prompting the researchers to delve deeper into this association. Dr. Leon Hsieh, the study’s lead author, noted that the team aimed to determine if these neutrophils were indeed being reprogrammed by the virus and whether this transformation contributed to the deterioration of the immune response. Utilizing blood samples from hospitalized COVID-19 patients, they compared the neutrophils of individuals who developed severe symptoms with those of healthy controls, revealing stark differences in their functionality.

The findings revealed that the neutrophils from patients with severe COVID-19 displayed significant degranulation and differentiation into PMN-MDSCs. This process, which involves the release of granular contents into the extracellular space, impairs the immune system’s capacity to detect and counteract the viral threat effectively. The study potentially represents a pioneering observation of PMN-MDSCs in a respiratory viral infection, challenging preconceived notions about the role of neutrophils in viral diseases.

A closer examination revealed that PMN-MDSCs possess surface proteins known to negatively influence T cell activity. Among these are lectin-type oxidized low-density lipoprotein receptor-1 (LOX-1) and programmed cell death ligand 1 (PD-L1), with the latter being particularly notorious for its role in dampening T cell activation. By binding to the PD-1 receptor on T cells, PD-L1 inhibits crucial processes such as T cell proliferation and the release of signaling proteins known as cytokines, which are pivotal in orchestrating the immune response against infections.

The research team took their investigations a step further by co-culturing neutrophils with SARS-CoV-2 in laboratory conditions. The results were telling: the neutrophils underwent differentiation into PMN-MDSCs capable of suppressing T cell proliferation and diminishing cytokine production, thereby weakening the immune response. Interestingly, when the researchers subjected neutrophils to the H1N1 influenza virus, they did not observe a similar conversion to PMN-MDSCs, suggesting that SARS-CoV-2 exhibits unique pathogenic strategies that may not be replicated by other viruses.

In light of these findings, Dr. Cox emphasized the necessity of understanding how SARS-CoV-2 prompts such drastic changes in neutrophil behavior and the potential therapeutic avenues that could arise from this knowledge. For instance, the study explored the possibility of leveraging antibodies against PD-L1, which have been previously used in cancer therapies, to mitigate the immune suppression caused by PMN-MDSCs in COVID-19 patients. In laboratory experiments, the introduction of PD-L1 antibodies resulted in reduced T cell suppression and enhanced T cell activity, indicating a possible multi-faceted approach to combatting severe COVID-19.

By offering insights into the immune system’s malfunctions induced by SARS-CoV-2, this research not only contributes to the foundational understanding of COVID-19 pathogenesis but also heralds the potential for novel therapeutic strategies. The findings position researchers to investigate how existing treatments can be optimized and possibly combined with antiviral medications to improve outcomes for patients facing severe disease.

Understanding these immune responses lays the groundwork for future research aimed at unraveling the complexities of COVID-19, particularly in populations at higher risk due to age or comorbidities. Importantly, uncovering the mechanisms behind neutrophil transformation may also lead to greater insights into the myriad ways infectious diseases can manipulate the immune system for their advantage.

As researchers continue to uncover the nuances of immune interactions with SARS-CoV-2, the hope is to identify markers that can predict disease severity, ultimately leading to tailor-made treatment plans that enhance recovery and survival. In this ongoing battle against COVID-19, the study stands out as a crucial step toward empowering the immune system to reclaim its defensive capabilities.

In conclusion, the transformational impact of SARS-CoV-2 on neutrophil function illustrates the intricacies of immune evasion strategies employed by viruses. With knowledge derived from this essential work, the pathway toward innovative therapeutic solutions for severe COVID-19 becomes clearer, holding promise for future research and enabling more effective health responses to viral infectious diseases.

Subject of Research: Transformation of Neutrophils by SARS-CoV-2
Article Title: New Insights into Neutrophil Transformation: The Role of SARS-CoV-2 in Severe COVID-19
News Publication Date: (Not Provided)
Web References: (Not Provided)
References: (Not Provided)
Image Credits: (Not Provided)

Keywords